Novo Nordisk, manufacturer of the weight loss jab Wegovy, has been reprimanded for allegedly failing to disclose or accurately report payments to healthcare and patient organisations (Alamy/PA ...
Director General, Creative Industries and Trade, Ramzi Saad Director General, Digital and Creative Marketplace Frameworks, Amy Awad Director General, Arts and Cultural Sector Strategy, Madona Radi ...
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...
Novo Nordisk A/S Trading Down 3.7 % Shares of NYSE NVO opened at $78.78 on Friday. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company has a market cap of $353.52 ...
Department of Materials Science and Engineering, University of California, Irvine, Irvine, California 92697, United States Department of Chemistry, Boston University, Boston, Massachusetts 02215, ...
Global re/insurance specialist MAPFRE Re announced that it is restructuring its organization ... Sanzo remains the senior executive. MAPFRE Re also noted that the management of business ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 7 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their ...
The December trial results showed that only 57.3% of patients achieved the highest dose, creating market concerns about potential side effects or adequate weight management at lower doses. CagriSema ...
Novo Nordisk A/S today announced 2024 earnings ... impacting the stock price. Management outlined plans to submit for approval in '26. With strong 2025 guidance and potential new approvals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback